{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:56:57Z","timestamp":1790251017737,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.humpath.2009.10.002","type":"journal-article","created":{"date-parts":[[2009,12,30]],"date-time":"2009-12-30T09:13:10Z","timestamp":1262164390000},"page":"485-492","source":"Crossref","is-referenced-by-count":62,"title":["Epidermal growth factor receptor and HER-2\/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder"],"prefix":"10.1016","volume":"41","author":[{"given":"Nafis","family":"Shafizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Grenert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2009.10.002_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jamcollsurg.2008.04.031","article-title":"Intrahepatic cholangiocarcinoma: a malignancy of increasing importance","volume":"207","author":"Hammill","year":"2008","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.humpath.2009.10.002_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jamcollsurg.2008.09.007","article-title":"Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature","volume":"208","author":"Aljiffry","year":"2009","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.humpath.2009.10.002_bib3","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1055\/s-2004-828889","article-title":"The epidemiology of cholangiocarcinoma","volume":"24","author":"Shaib","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.humpath.2009.10.002_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s11605-006-0075-x","article-title":"Diagnosis and surgical management of gallbladder cancer: a review","volume":"11","author":"Reid","year":"2007","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.humpath.2009.10.002_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1177\/000313480407000901","article-title":"Cholangiocarcinoma: advocate an aggressive approach with adjuvant chemotherapy","volume":"70","author":"Kelley","year":"2004","journal-title":"Am Surg"},{"key":"10.1016\/j.humpath.2009.10.002_bib6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/cncr.10831","article-title":"Is post-operative chemotherapy useful for gallbladder carcinoma? A phase III multi-center prospective randomized controlled trial in patients with resectable pancreatobiliary carcinoma","volume":"95","author":"Takada","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.humpath.2009.10.002_bib7","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1053\/gast.2002.32410","article-title":"Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line","volume":"122","author":"Yoon","year":"2002","journal-title":"Gastroenterology"},{"issue":"18 Suppl","key":"10.1016\/j.humpath.2009.10.002_bib8","first-page":"1S","article-title":"Targeting the epidermal growth factor receptor for cancer therapy","volume":"20","author":"Mendelsohn","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2009.10.002_bib9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11912-005-0034-9","article-title":"Clinical experience with monoclonal antibodies to epidermal growth factor receptor","volume":"7","author":"Calvo","year":"2005","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.humpath.2009.10.002_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2119\/molmed.2009.00007","article-title":"Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumours","volume":"15","author":"Argyriou","year":"2009","journal-title":"Mol Med"},{"key":"10.1016\/j.humpath.2009.10.002_bib11","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ctrv.2009.02.001","article-title":"Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment","volume":"35","author":"Capdevila","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.humpath.2009.10.002_bib12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/01.cad.0000217433.48870.37","article-title":"Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib","volume":"17","author":"Wiedmann","year":"2006","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.humpath.2009.10.002_bib13","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1471-2407-6-190","article-title":"Gemcitabine in combination with EGFR antibody (cetuximab) as a treatment of cholangiocarcinoma: a case report","volume":"6","author":"Sprinzl","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.humpath.2009.10.002_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000111117","article-title":"Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas","volume":"72","author":"Paule","year":"2007","journal-title":"Oncology"},{"key":"10.1016\/j.humpath.2009.10.002_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000098853","article-title":"Effects of the anti-epidermal growth factor receptor cetuximab on cholangiocarcinoma of the liver","volume":"30","author":"Huang","year":"2007","journal-title":"Onkologie"},{"key":"10.1016\/j.humpath.2009.10.002_bib16","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2005.05.3579","article-title":"Phase II study of erlotinib in patients with advanced biliary cancer","volume":"24","author":"Philip","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2009.10.002_bib17","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-05-1692","article-title":"Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma","volume":"12","author":"Leone","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2009.10.002_bib18","first-page":"157","article-title":"Simultaneous detection of epidermal growth factor receptor, epidermal growth factor, and ras p21 in cholangiocarcinoma by an immunocytochemical method","volume":"3","author":"Nonomura","year":"1998","journal-title":"Liver"},{"key":"10.1016\/j.humpath.2009.10.002_bib19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1078\/0344-0338-00016","article-title":"Expression and clinical significance of the erbB family in intrahepatic cholangiocellular carcinoma","volume":"197","author":"Ito","year":"2001","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.humpath.2009.10.002_bib20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S1590-8658(03)00077-X","article-title":"Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours","volume":"35","author":"Altimari","year":"2003","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.humpath.2009.10.002_bib21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/01.sla.0000129492.95311.f2","article-title":"Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: appraisal of an animal model of cholangiocarcinoma","volume":"240","author":"Jan","year":"2004","journal-title":"Ann Surg"},{"key":"10.1016\/j.humpath.2009.10.002_bib22","doi-asserted-by":"crossref","first-page":"52","DOI":"10.14309\/00000434-200509001-00086","article-title":"Expression of epidermal growth factor receptor, ErbB2, and matrix metalloproteinase-9 in hepatolithiasis and cholangiocarcinoma","volume":"45","author":"Kim","year":"2005","journal-title":"Korean J Gastro"},{"key":"10.1016\/j.humpath.2009.10.002_bib23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.1779","article-title":"Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers","volume":"206","author":"Nakazawa","year":"2005","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2009.10.002_bib24","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathologic and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2009.10.002_bib25","doi-asserted-by":"crossref","first-page":"285","DOI":"10.7150\/ijms.5.285","article-title":"EGFR expression in gallbladder carcinoma in North America","volume":"5","author":"Kaufman","year":"2008","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.humpath.2009.10.002_bib26","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0168-8278(02)00057-0","article-title":"Gene amplification and mRNA and protein overexpression of c-erbB-2 (HER-2\/neu) in human intrahepatic cholangiocarcinoma as detected by fluorescence in situ hybridization, in situ hybridization, and immunohistochemistry","volume":"36","author":"Ukita","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.humpath.2009.10.002_bib27","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jcp.2005.026575","article-title":"FAT, e-cadherin, beta catenin, Her-2\/neu, Ki-67 immunoexpression, and histologic grade in intrahepatic cholangiocarcinoma","volume":"58","author":"Settakorn","year":"2005","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.humpath.2009.10.002_bib28","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/annonc\/mdm006","article-title":"Gene amplification and protein overexpression of HER-2\/neu in human extrahepatic cholangiocarcinoma as detected by chromogenic in situ hybridization and immunohistochemistry: its prognostic implication in node positive patients","volume":"18","author":"Kim","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.humpath.2009.10.002_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0014-4827(02)00098-8","article-title":"Epidermal growth factor receptor: mechanisms of activation and signaling","volume":"284","author":"Jorissen","year":"2003","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.humpath.2009.10.002_bib30","first-page":"1","article-title":"Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage","volume":"63","author":"Kari","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.humpath.2009.10.002_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00019606-200403000-00001","article-title":"Evaluation of epidermal growth factor receptor (EGFR) by chromogenic in situ hybridization (CISH) and immunohistochemistry (IHC) in archival gliomas using bright-field microscopy","volume":"13","author":"Marquez","year":"2004","journal-title":"Diagn Mol Pathol"},{"key":"10.1016\/j.humpath.2009.10.002_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/00313029109063564","article-title":"A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas","volume":"23","author":"Kearsley","year":"1991","journal-title":"Pathology"},{"key":"10.1016\/j.humpath.2009.10.002_bib33","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2003.11.069","article-title":"Epidermal growth factor receptor in non\u2013small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis","volume":"21","author":"Hirsch","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2009.10.002_bib34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/modpathol.3800608","article-title":"Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification","volume":"19","author":"Alvarez","year":"2006","journal-title":"Mod Path"},{"key":"10.1016\/j.humpath.2009.10.002_bib35","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.humpath.2005.12.009","article-title":"Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma","volume":"37","author":"Buckley","year":"2006","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2009.10.002_bib36","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1309\/WF10QAAED3PP93BH","article-title":"Epidermal growth factor receptor and gene copy number in conventional hepatocellular carcinoma","volume":"129","author":"Buckley","year":"2008","journal-title":"Am J Clin Path"},{"key":"10.1016\/j.humpath.2009.10.002_bib37","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2009.10.002_bib38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.pai.0000213141.47277.bf","article-title":"Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma","volume":"15","author":"Buckley","year":"2007","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.humpath.2009.10.002_bib39","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0165-4608(01)00460-5","article-title":"Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma","volume":"130","author":"Koo","year":"2001","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.humpath.2009.10.002_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1634\/theoncologist.7-suppl_4-31","article-title":"Epidermal growth factor receptor dependence in human tumors: more than just expression?","volume":"7","author":"Arteaga","year":"2002","journal-title":"Oncologist"},{"key":"10.1016\/j.humpath.2009.10.002_bib41","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2005.08.037","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry","volume":"23","author":"Chung","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2009.10.002_bib42","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.ejca.2005.03.018","article-title":"Assessing epidermal growth factor expression in tumors: what is the value of current test methods?","volume":"41","author":"Dei Tos","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.humpath.2009.10.002_bib43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","article-title":"Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study","volume":"6","author":"Moroni","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.humpath.2009.10.002_bib44","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/jnci\/dji112","article-title":"Epidermal growth factor receptor gene and protein and Gefitinib sensitivity in non\u2013small-cell lung cancer","volume":"97","author":"Cappuzzo","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.humpath.2009.10.002_bib45","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1200\/JCO.2006.09.4300","article-title":"Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive\/phospho-Akt-positive or never smoker patients with advanced non\u2013small-cell lung cancer: the ONCOBELL trial","volume":"25","author":"Cappuzzo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2009.10.002_bib46","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/sj.bjc.6604988","article-title":"Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma","volume":"100","author":"Yoshikawa","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.humpath.2009.10.002_bib47","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s00432-005-0016-1","article-title":"Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas","volume":"131","author":"Gwak","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.humpath.2009.10.002_bib48","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non\u2013small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"New England J Med"},{"key":"10.1016\/j.humpath.2009.10.002_bib49","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2559.2002.00353.x","article-title":"c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma","volume":"40","author":"Aishima","year":"2002","journal-title":"Histopathology"},{"key":"10.1016\/j.humpath.2009.10.002_bib50","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-2559.1998.00496.x","article-title":"c-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma","volume":"33","author":"Terada","year":"1998","journal-title":"Histopathology"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817709003669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817709003669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T09:34:19Z","timestamp":1685352859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817709003669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0046817709003669"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2009.10.002","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}